Presentations developed in cooperation with GARDP, CARB-X, and REPAIR Impact Fund. Antimicrobial resistance (AMR) continues to be a major problem that is not being addressed adequately by the pharmaceutical industry. Academic research is more frequently serving as a source for novel antimicrobial agents to treat infections caused by antibiotic-resistant organisms. In this session, drug discovery efforts originating from academic laboratories will be discussed. The importance of collaborative efforts will be emphasized.

Speakers include Kevin Outterson, Executive Director of CARB-X. The Royal Swedish Academy of Engineering Sciences (IVA) is hosting the yearly conference for the International Council of Academies of Engineering and Technological Sciences (CAETS) in 2019. CAETS in a independent non-political, non-governmental international organization of engineering and technological science academies worldwide. The conference will focus on what engineering and technological science has accomplished in the last 100 years as well as future challenges, focusing on the topics of Health, Energy, Affordable Living, Superintelligens…

The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this webinar, Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Catholic University of Louvain (FR), will talk about intracellular activity of antibiotics. Topics discussed will include: The role of intracellular survival in chronic infections and its contribution to poor response to antibiotics In vitro models to…

Please share any pipeline additions and changes that you are aware of by 22 July 2019. Download and use this form to provide updates. The latest pipeline update (as of July 1, 2018), can be found as a manuscript (Theuretzbacher et al. Lancet ID 2018), and as a set of summary tables. Contact Sarah Paulin (paulins@who.int).

This is an open session hosted by the National Academy of Sciences, Engineering, and Medicine.  The 1.5-day public workshop to will be held on July 24-25, 2019 in Washington, D.C and focus on the translation of federal investments in biomedical science to innovation in drug development and how the public benefits from that investment in terms of drug pricing and access. The meeting will feature invited presentations and panel discussions on topics that may include:   how federal funding for…

Keynote lecture given by Kevin Outterson, Executive Director of CARB-X. Additional details forthcoming.

The ASM/ECSMID Conference on Drug Development returns to Boston, Massachusetts for 2019. Check back soon for program details. Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by National and International bodies. There are relatively few agents in developmental pipelines and a paucity of identified microbiological targets that can be exploited for drug development. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology…